Typical real-world nonadherence of 30-50%1 undermines marketing and sales investment, which in turn can erode launch success, leaving you vulnerable to competitors and lengthening the time to peak sales.
We apply behavioural science to inform a better understanding of a patient’s and HCP’s mindset, enabling marketing and sales teams to optimise the effectiveness of their engagement.
TARA™ (Treatment Activation and Adherence Risk Assessment) Segments patients by their risk of nonadherence, identifying why patients may be nonadherent and proposing evidence-based activators that we know reduce the risk of nonadherence.
We apply the principles of behavioural science to help you increase the effectiveness of Sales Rep to HCP engagement.
Our scientifically grounded development of messaging is proven to enhance patient engagement with their medicine.
Our recognised experts will help you identify, understand and reduce behavioural risk in your brand strategy.
1. World Health Organization (2003) Adherence to long-term therapies: evidence for action. Geneva: World Health Organization. Available at https://iris.who.int/items/bf8058c0-03b2-4b47-838f-5534849927fb.